Short answer
Designers of health-related products and interventions must focus on measurable improvements in user health and well-being, aiming for broad applicability where possible.
- Field
- User-Centred Design
- Source
- New England Journal of Medicine (2020)
- Method
- Randomized Controlled Trial (RCT)
- Sample
- 3730 participants
- Evidence
- Strong effect
The drug empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure in patients with recommended therapy, irrespective of their diabetes status. This user-centred design research insight is drawn from a 2020 study published in New England Journal of Medicine. Using Randomized controlled trial (rct) with 3730 participants, researchers explored how this design variable affects real-world outcomes. The key design takeaway: Designers of health-related products and interventions must focus on measurable improvements in user health and well-being, aiming for broad applicability where possible.
Empagliflozin reduces heart failure hospitalizations by 30% in patients with reduced ejection fraction
The drug empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure in patients with recommended therapy, irrespective of their diabetes status.
New England Journal of Medicine · 2020
Key Findings
- 01Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure by 30% compared to placebo.
- 02The benefit of empagliflozin was consistent across patients with and without diabetes.
Application
Design takeaway
Designers of health-related products and interventions must focus on measurable improvements in user health and well-being, aiming for broad applicability where possible.
How to apply
When designing any product or service that impacts health, prioritize evidence-based improvements in user health metrics and consider the diverse needs of the target user group.
Project actions
- 01When designing a product, think about how it directly impacts the user's health and well-being.
- 02Consider if your design can benefit a wide range of users, not just a very specific group.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Large sample size provides statistical power.
- +Randomized controlled trial design minimizes bias.
Limitations
The study was conducted in a controlled clinical setting and may not fully reflect real-world adherence or effectiveness. The specific mechanism of action of empagliflozin is complex and not fully detailed here.
Reliability & validity
The study's reliability is high due to its RCT design and large sample size. Validity is strong for the specific population studied, but generalizability to other heart failure types or patient demographics may be limited.
Think critically
To what extent can the findings of a highly controlled clinical trial be directly applied to the design of everyday consumer products, and what are the ethical considerations when 'designing' for health outcomes?
Design Principles
"Interventions should demonstrably improve user health outcomes and quality of life, with a focus on efficacy across diverse user populations."
This research highlights how pharmaceutical interventions, a form of product development, can directly improve user (patient) well-being and quality of life by mitigating severe health events. It underscores the importance of considering the user's physiological state and the impact of designed interventions on their daily experience and long-term health outcomes.
What This Means for Your Design
A new medicine called empagliflozin helps people with heart failure by making them less likely to die or go to the hospital for their condition, and it works for people with or without diabetes.
How to use in your project
- 1.If your project involves a health-related product, you can cite this to show the importance of designing for improved health outcomes and user quality of life.
- 2.Use this to justify the need for your design to address a specific health issue or improve a user's physiological state.
Add to My Project
Quick Cite
Paragraph starter
The EMPEROR-Reduced trial demonstrated that empagliflozin significantly reduced cardiovascular death or heart failure hospitalizations by 30% in patients with heart failure and reduced ejection fraction, irrespective of diabetes status. This highlights the critical role of designed pharmaceutical interventions in improving user health outcomes and quality of life, a key consideration for any user-centred design approach.
Source
New England Journal of Medicine
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
journal · 2020
View sourceQuestions About This Research
- What does the research say about empagliflozin reduces heart failure hospitalizations by 30% in patients with reduced ejection fraction?
- Designers of health-related products and interventions must focus on measurable improvements in user health and well-being, aiming for broad applicability where possible. Evidence: New England Journal of Medicine (2020).
- Why does "Empagliflozin reduces heart failure hospitalizations by 30% in patients with reduced ejection fraction" matter for design?
- This research highlights how pharmaceutical interventions, a form of product development, can directly improve user (patient) well-being and quality of life by mitigating severe health events. It underscores the importance of considering the user's physiological state and the impact of designed interventions on their daily experience and long-term health outcomes.
- How can designers apply this research?
- Designers of health-related products and interventions must focus on measurable improvements in user health and well-being, aiming for broad applicability where possible.
- What were the main findings?
- Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure by 30% compared to placebo.. The benefit of empagliflozin was consistent across patients with and without diabetes.
- What research method was used?
- Randomized Controlled Trial (RCT) with 3730 participants.
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2020 journal from New England Journal of Medicine.
- What should I do differently in my next project?
- When designing any product or service that impacts health, prioritize evidence-based improvements in user health metrics and consider the diverse needs of the target user group.
- What are the limitations?
- The study focused on specific types of heart failure (reduced ejection fraction) and may not be generalizable to all heart failure patients. Long-term effects beyond the study period are not fully captured.